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TGF-b signaling regulates a variety of cellular
processes, including proliferation, apoptosis, dif-
ferentiation, immune responses, and fibrogenesis.
Here, we describe a lysine methylation-mediated
mechanism that controls the pro-fibrogenic activity
of TGF-b. We find that the methyltransferase Set9
potentiates TGF-b signaling by targeting Smad7,
an inhibitory downstream effector. Smad7 methyl-
ation promotes interaction with the E3 ligase Arka-
dia and, thus, ubiquitination-dependent degrada-
tion. Depletion or pharmacological inhibition of
Set9 results in elevated Smad7 protein levels and
inhibits TGF-b-dependent expression of genes en-
coding extracellular matrix components. The inhib-
itory effect of Set9 on TGF-b-mediated extracel-
lular matrix production is further demonstrated in
mouse models of pulmonary fibrosis. Lung fibrosis
induced by bleomycin or Ad-TGF-b treatment was
highly compromised in Set9-deficient mice. These
results uncover a complex regulatory interplay
among multiple Smad7 modifications and highlight
the possibility that protein methyltransferases may
represent promising therapeutic targets for treating
lung fibrosis.INTRODUCTION
TGF-b is a pleiotropic cytokine involved in the regulation of cell
fate determination, extracellular matrix (ECM) production, cell
growth, motility, differentiation, and the immune response (Mas-
sague´, 2012; Travis and Sheppard, 2014; Lamouille et al., 2014;
ten Dijke and Hill, 2004; Wakefield and Hill, 2013). TGF-b cyto-
kines bind to type I and type II serine-threonine kinase receptors
and transmit their signals through Smad proteins. Receptor-
regulated Smads (R-Smads; Smad2 and Smad3) are directly
phosphorylated by type I receptor kinases to form a heteromeric
complex with the Co-Smad protein Smad4, which can translo-Cell
This is an open access article under the CC BY-Ncate to the nucleus and regulate target gene transcription
(Massague´, 2012; ten Dijke and Hill, 2004; Wakefield and Hill,
2013). The pathway is under control by the inhibitory Smad7,
which escorts E3-ubiquitin ligases (Smurf1 and Smurf2) to the
plasma membrane and facilitates the proteasomal destruction
of TGF-b receptors and also itself (Ebisawa et al., 2001; Kavsak
et al., 2000; Yan et al., 2009; Gro¨nroos et al., 2002; Ogunjimi
et al., 2005; Simonsson et al., 2005).
Dysfunction of TGF-b signaling has been implicated in the
pathogenesis of fibrotic diseases, rheumatoid arthritis, and
cancer (Blobe et al., 2000). In particular, TGF-b signaling plays
a central role in the development of pulmonary fibrosis by
promoting the proliferation and transdifferentiation of lung fi-
broblasts and epithelial cells to collagen-producing myofibro-
blasts (Wynn, 2011). Although the link between TGF-b signaling
and pulmonary fibrosis was identified two decades ago (Border
and Noble, 1994), little progress has been made in pharmaco-
logical intervention strategies for this fatal disease. Effective
therapy could be achieved by targeting the profibrogenic activ-
ity of TGF-b.
A potential strategy toward the above goal would involve tar-
geting posttranslational modifications of proteins involved in
the regulation of the pathway. Apart from the phosphorylation
and ubiquitination described above, Smad proteins are also sub-
ject to regulation by other modifications. For example, Smad7
can be acetylated by the histone acetyltransferase p300 at
lysine-64 and lysine-70, which antagonizes its ubiquitination
and degradation (Gro¨nroos et al., 2002; Simonsson et al.,
2005). The BMP-signaling effector molecule Smad6 interacts
with the protein arginine methyltransferase PRMT and is di-
methylated at arginine-74 and -81 residues (Inamitsu et al.,
2006; Xu et al., 2013). Arginine-74-methylated Smad6 is released
from the type I receptor and facilitates the initial steps of the
BMP-signaling pathway via de-repression of Smad1/5 (Xu
et al., 2013).
Here we show that Set9 methylates Smad7, the inhibitory
Smad of the TGF-b-signaling pathway, and influences the profi-
brogenic effects of TGF-b by modulating the expression of ECM
genes. Set9 (SETD7; KMT7) is the foundingmember of themeth-
yltransferase enzymes, which canmethylate non-histone protein
substrates, including the transcription factors TAF10, p53, Stat3,
E2F1, Rb, ERa, NF-kB, and DNMT1 (Kouskouti et al., 2004;Reports 15, 2733–2744, June 21, 2016 ª 2016 The Author(s). 2733
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Chuikov et al., 2004; Yang et al., 2010; Kontaki and Talianidis,
2010a; Carr et al., 2011; Munro et al., 2010; Subramanian
et al., 2008; Pradhan et al., 2009; Sarris et al., 2014; Hamamoto
et al., 2015). Methylation can regulate transcription factor func-
tion in many different ways: it can modulate protein stability,
the deposition of other modifications, nuclear retention and
recruitment to genomic targets, transactivation potential, and
interaction with other proteins (Sarris et al., 2014). Depending
on the substrate, Set9 regulates various signaling and develop-
mental pathways. Despite the plethora of studies in different
cell lines, the in vivo function of Set9 in animals remains
unexplored.
The results presented here suggest that Set9-dependent
methylation and consequent modulation of Smad7 protein
stability plays a central role in TGF-b-dependent activation of
ECM genes and the development of pulmonary fibrosis. Inhibi-
tion of Set9 has a protective effect against cellular damage- or
cytokine-induced pulmonary fibrosis.
RESULTS
Set9 Is Required for TGF-b-Mediated Activation of ECM
Genes
To gain insight into the in vivo function of Set9, we generated a
knockout (KO) mouse model by deleting exon-4 of the Setd7
gene (Figures S1A–S1C). Mice with homozygous deletions
(Set9-KO) develop normally and are fertile. Examination of
2-month-old Set9-KO mice did not reveal visible phenotypes.
To expose potential hidden phenotypes, we isolated primary
lung fibroblasts from wild-type (WT) and Set9-KOmice and sub-
jected them to different induction conditions. The initial data indi-
cated that the steady-state mRNA levels of several ECM genes
were decreased in Set9-deficient cells. Since TGF-b-signaling
pathway plays a key role in the regulation of ECM gene expres-
sion (Wynn, 2011), we tested the effect of Set9 inactivation in
TGF-b-dependent gene activation. As expected, the mRNA
levels of several ECM genes, including Col1A1, Col3A1,
Col4A1, Fbn, Itg5A, Krt17, Col7A1, Serpine1, and Ctgf, were
highly increased in TGF-b-treatedWT cells, reaching amaximum
at different time periods after treatment (Figure 1A). However,
TGF-b-dependent stimulation of all of the studied ECM genes
was greatly compromised in fibroblasts isolated from Set9-KO
mice (Figure 1A).
Co-treatment of WT cells with a newly characterized, cell-
permeable, highly specific Set9 inhibitor, (R)-PFI-2 (Barsyte-
Lovejoy et al., 2014), also prevented TGF-b-dependent activa-
tion of ECM genes (Figure 1A). The specificity of the effect was
confirmed by the lack of inhibition in cells treated with the
inactive enantiomer (S)-PFI-2 (Figure 1A). Similar to primary fi-
broblasts, TGF-b-mediated stimulation of a panel of ECM
genes was diminished in the human cervical carcinoma
HeLa cell line following small hairpin RNA (shRNA)-mediated
knockdown of Set9 or upon inhibition of Set9 enzymatic activ-
ity by (R)-PFI-2 treatment (Figure 1B). Since TGF-b or (R)-PFI-2
inhibitor treatment did not influence the protein levels of
Set9 (Figures S1D and S1E), the above results demonstrate
that Set9 enzymatic activity is required for TGF-b-dependent
activation of ECM genes. The effect of Set9 inactivation also2734 Cell Reports 15, 2733–2744, June 21, 2016was observed on other classes of TGF-b-regulated genes,
including HmgA2, Has2, Twist, and Snai1, which regulate
epithelial-mesenchymal transition (EMT) (Valcourt et al.,
2005; Moustakas and Heldin, 2014) (Figure S1F). The high
number of genes affected indicates that Set9 may not function
in a gene-specific manner but at a more upstream level of the
signaling pathway.
Set9 Methylates Smad7 at Lysine-70 Residue and
Regulates Its Stability
To investigate the molecular mechanism, we first tested the role
of p53, a known substrate of Set9 (Chuikov et al., 2004), which
can cooperate with Smad proteins to mediate TGF-b responses
(Cordenonsi et al., 2003). Loss of Set9 in lung fibroblasts did
not affect TGF-b-mediated stabilization of p53 (Figure S1G).
Furthermore, in p53-deficient H1299 lung carcinoma cells,
Set9 depletion greatly compromised TGF-b-dependent activa-
tion of COL7A1, SERPINE1, and CTGF expression (Figure S1H),
demonstrating that p53 is not required for Set9-dependent mod-
ulation of ECM gene expression.
Next we investigated whether Smad proteins, the main down-
stream effectors of the pathway, are potential enzymatic sub-
strates of Set9. In vitro methylation assays performed with
Smad2, Smad3, Smad4, and Smad7 recombinant proteins re-
vealed that only Smad7 could bemethylated by Set9 (Figure 2A).
Methylation of Smad7 in vitro was sensitive to nanomolar con-
centrations of (R)-PFI-2, but not to (S)-PFI-2 (Figure 2B). Mass
spectrometry (MS) analysis was used to identify sites of methyl-
ation on in-vitro-methylated Smad7 protein. We detected 28
tryptic and four AspN-specific peptides in total, covering 57%
of the Smad7 sequence. Accurate mass measurement revealed
one mono-methylated peptide of 26 amino acids, and tandem
MS identified lysine-70 as the site of methylation (Figure S2).
No corresponding non-methylated peptide was identified, as
the non-methylated lysine would be subject to tryptic digestion
in contrast to the methylated one. Indeed, we identified the
23-amino acid-long peptide starting at the glycine following
lysine-70. To verify the MS results, we constructed a mutant
Smad7 replacing the identified lysine with an arginine. The
K70R mutant was not methylated, suggesting that K70 is the
main methylation site of Smad7 (Figure 2A).
These data indicated that Smad7 is a primary candidate target
through which Set9 exerts its modulatory function on ECM gene
regulation. This was confirmed by the data showing rescue of
TGF-b-mediated inducibility of gene expression in Set9-deficient
HeLa cells when Smad7 also was depleted by small interfering
RNA (siRNA). As expected, knockdown of Smad7 resulted in
elevated steady-state- and TGF-b-induced mRNA levels of
COL4A2, FN, FBN, ITG5A, KRT16, and SERPINE1 genes (Fig-
ures S2B and S2C). Importantly, increased expression of these
genes was also observed in Set9-depleted cells after Smad7
knockdown (Figure S2B), suggesting that Set9-mediated regula-
tion of ECM genes requires Smad7.
To examine the effect of methylation of Smad7 in vivo, we
generated a methyl-specific Smad7 antibody, whose specificity
was verified using in-vitro-methylated proteins (Figure S3).
Methylated endogenous Smad7 was readily detected in extracts
of lung fibroblasts or HeLa cells that were treated with the
AB
Figure 1. Set9-Dependent Regulation of TGF-
b-Induced Expression of Extracellular Matrix
Genes
(A) qPCR analysis of the mRNA levels of the indicated
panel of extracellular matrix (ECM) genes in isolated
primary lung fibroblasts that were treated in vitro with
5 ng/ml TGF-b for the indicated time periods (h, hours).
Lung fibroblasts were from wild-type mice (WT, black
bars) or Set9-KO mice (gray bars). WT mice were
treatedwith 1 mM (R)-PFI-2 Set9 inhibitor (white bars) or
with 1 mM (S)-PFI-2 inactive enantiomer (stripped bars).
Bars represent mean values ofmRNA levels normalized
to Gapdh mRNA ± SEM from four experiments per-
formed in triplicates (*p < 0.05, two-tailed Student’s
t test).
(B) qPCR analysis of mRNA from WT HeLa cells and
HeLa cells stably expressing sh-Set9 (sh-Set9). Treat-
ments and analyses were performed as in (A).
See also Figure S1.proteasome inhibitorMG132 (Figure 2C). In untreated cells, how-
ever, the methyl-Smad7 signal could hardly be detected, and it
was completely absent in extracts from Set9-KO lung fibroblasts
or sh-Set9-expressing HeLa cells (Figure 2C). The above results
suggest that methylation leads to destabilization of Smad7.
This scenario was further supported by the detection of highlyCeelevated total Smad7 protein levels in sh-
Set9 HeLa cells and in Set9-KO lung fibro-
blasts (Figure 2C). In fact, the amount of total
Smad7 in untreated Set9-deficient cells was
similar to that detected in MG132-treated
WT cells and was not increased further by
MG132 treatment (Figure 2C). In agreement
with the above, the half-life of endogenous
Smad7 significantly increased in Set9-defi-
cient lung fibroblasts and Set-9-depleted
HeLa cells (Figure 2D). In transfection ex-
periments, overexpression of WT Set9, but
not its enzymatically inactive mutant form
(Set9H297A), resulted in decreased half-life
of Smad7 protein (Figure 2E). When anti-
MeSmad7 antibody was used in the assays,
the signal corresponding to methylated
Smad7 protein was largely lost already 1 hr
after protein synthesis inhibition, suggesting
that the methylated form of Smad7 is pre-
disposed to degradation. In agreement with
this, the protein levels of Smad7K70R mutant
remained more stable during the 6-hr time
frame of the assay (Figure 2E).
Previous studies have established that
Smad7 stability is regulated by interplay
between acetylation and ubiquitination at
lysine residues K64 and K70 (Gro¨nroos
et al., 2002; Ogunjimi et al., 2005; Simonsson
et al., 2005). Acetylation stabilizes Smad7 by
competing with Smurf-dependent ubiquiti-
nation and subsequent proteasomal degra-
dation. To understand the mechanism of
methylation-mediated destabilization of Smad7, we investi-
gated the possibility of a crosstalk among methylation, acetyla-
tion, and ubiquitination. Since lysine-70 is a common target for
Set9-mediated methylation and p300-mediated acetylation,
these modifications should be mutually exclusive. In agreement
with this, an acetylation-specific antibody did not recognizell Reports 15, 2733–2744, June 21, 2016 2735
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Figure 2. Set9 Methylates Smad7 and Mod-
ulates Smad7 Stability
(A and B) Set9 methylates Smad7. Fluorographs
and Coomassie blue-stained gels of in vitro
methylation reactions carried out with the indi-
cated recombinant Smad proteins and p53 as
positive control are shown. Where indicated in (B),
(R)-PFI-2 and (S)-PFI-2 also were included in the
reactions.
(C) Western blot analysis, with the indicated
antibodies recognizing all forms of Smad7 pro-
teins (aSmad7) or K70-methylated Smad7 (aMe-
Smad7) and Gapdh, was performed in whole-cell
extracts from WT and Set9-depleted (sh-Set9)
HeLa cells or primary lung fibroblasts fromWT and
Set9-KOmice. The cells were treated with 5 ng/ml
TGF-b and, where indicated (+), with 5 mMMG132
for 5 hr.
(D) WT and sh-Set9 HeLa cells or WT and Set9-KO
lung fibroblasts were treated with 100 mg/ml
cycloheximide (CHX). Representative western
blots of whole-cell extracts prepared at the indi-
cated time points following CHX addition with
aSmad7 antibody are shown. Graphs show
average band intensities, measured by ImageJ,
±SEM relative to untreated controls from three
experiments.
(E) HeLa cells were transfected with the indicated
combinations of HA-tagged WT (HA-Smad7wt) or
K70R non-methylatable mutant form of Smad7
and myc-tagged WT (Set9wt) or enzymatically
inactive H297A mutant form of Set9 expression
vectors. Then 2 days after transfection, the cells
were treated with 50 mg/ml CHX for the indicated
times. Whole-cell extracts were analyzed in
western blots using anti-HA (a-HA) antibodies
(upper panels) or anti-Me-Smad7 antibody (bot-
tom panel) to estimate the amounts of total Smad7
and methylated Smad7 proteins. One represen-
tative of two experiments is shown. The graph
shows band intensities, measured by ImageJ
software, relative to untreated controls.
See also Figure S2.methylated endogenous Smad7 in western blot assays, even
when the protein was stabilized by MG132 treatment (Fig-
ure 3A). Consistent with the increased stability of Smad7 in
Set9-deficient primary lung fibroblasts and in Set9-depleted
HeLa cells, these cells contained reduced amounts of endoge-
nous ubiquitinated protein after MG132 treatment, suggesting
that Set9-mediated methylation may stimulate Smad7 ubiquiti-
nation (Figure 3B). This notion was further supported by the re-
sults of in vivo ubiquitination assays using mutant forms of
Smad7. Overexpression of WT Set9, but not its enzymatically
inactive mutant form (Set9H297A), increased the amount of
ubiquitinated Smad7, while the Smad7K70R mutant was poorly
ubiquitinated (Figure 3C). Interestingly, mutation of lysine-642736 Cell Reports 15, 2733–2744, June 21, 2016also impaired Set9-mediated induction
of ubiquitination, suggesting that methyl-
ation at lysine-70 promotes ubiquitina-
tion mainly at the neighboring lysine-64
residue (Figure 3C).To understand howmethylation leads to increased ubiquitina-
tion and degradation of Smad7, we examined the physical
association of the methylated protein with Smurf1, Smurf2, and
Arkadia (RNF111), three known E3 ligases promoting Smad7
degradation (Gro¨nroos et al., 2002; Ogunjimi et al., 2005; Si-
monsson et al., 2005; Koinuma et al., 2003; Liu et al., 2006).
Co-immunoprecipitation (coIP) assays with methylation-specific
Smad7 antibody revealed that methylated Smad7 efficiently in-
teracts with Arkadia, but not with Smurf1 or Smurf2 (Figures
3D–3F). A much fainter Arkadia signal was detected in immuno-
precipitates recognizing total Smad7, which disappeared in
Set9-depleted primary lung fibroblasts or HeLa cells (Figure 3D).
On the contrary, immunoprecipitates with total Smad7 contained
similar amounts of Smurf1 or Smurf2 in extracts from both WT
and Set9-depleted cells (Figures 3E and 3F), corroborating the
conclusion that methylated Smad7 selectively interacts with
Arkadia.
Additional evidence for the selective interaction between
Arkadia and methylated Smad7 was provided by in vitro pull-
down assays using unmethylated or premethylated recombi-
nant Smad7 proteins and cellular extracts overexpressing
Arkadia, Smurf1, or Smurf2. As shown in Figure 4A, premethy-
lation of Smad7 by Set9 greatly increased interaction with
Arkadia, while it essentially diminished the interaction with
Smurf1 or Smurf2 proteins. The preferential association of
Arkadia with methylated Smad7 was surprising, since methyl-
ation occurs at the N-terminal region of the protein while Arka-
dia interacts only with the C-terminal domain (Koinuma et al.,
2003; Liu et al., 2006). To clarify the binding mechanism, we
performed the pull-down experiments using in-vitro-translated
Arkadia and Axin2 proteins. Axin2 is the partner of Arkadia,
which facilitates the formation of a multimeric complex with
Smad7 (Liu et al., 2006). We detected only a weak direct inter-
action between Arkadia and unmethylated Smad7, which was
marginally increased after methylation (Figure 4B, panel at left).
In contrast, Axin2 was strongly bound to both unmethylated
and methylated Smad7. Interestingly, however, inclusion of
Axin2 protein in the binding reaction resulted in a dramatic in-
crease of Arkadia-Smad7 interaction, which was absolutely
dependent on methylation (Figure 4B, panel at right). These re-
sults suggest that selective interaction of Arkadia with methyl-
ated Smad7 requires Axin2.
To provide direct functional evidence for the role of Arkadia
in destabilizing methylated Smad7, we depleted Arkadia in
HeLa cells by siRNA-mediated silencing. The endogenous
levels of Smad7 were increased about 2-fold in Arkadia-
depleted cells (Figure 4C). Importantly, the endogenous
amounts of methylated Smad7 increased more substantially,
reaching levels that could be easily and reproducibly detected
by western blots using Me-Smad7 antibody (Figure 4C). Set9
overexpression-mediated increased ubiquitination could not
be detected in Arkadia-depleted HeLa cells, while complemen-
tation of Arkadia, by overexpressing the mouse counterpart
that is not targeted by the siRNAs, resulted in increased levels
of Smad7 ubiquitination (Figure 4D). In agreement with this, the
half-life of total Smad7 and, importantly, that of methylated
Smad7 was greatly increased in Arkadia-depleted HeLa cells
(Figure 4E).
The above results demonstrate that Set9 regulates TGF-
b-signaling pathway via methylation-dependent destabilization
of Smad7, which is elicited primarily by the enhanced interaction
with the E3-ubiquitin ligase Arkadia. As a result of this effect,
elevated levels of Smad7 protein in Set9-deficient cells inhibit
TGF-b-dependent activation of ECM genes. Smad7 inhibits
TGF-b signaling by transfering Smurf1 and Smurf2 to the plasma
membrane, which triggers the proteasomal destruction of TGF-b
receptors (Ebisawa et al., 2001; Kavsak et al., 2000; Yan et al.,
2009; Gro¨nroos et al., 2002; Ogunjimi et al., 2005; Simonsson
et al., 2005). In agreement with this, the endogenous levels of
TGF-b receptor I protein (TGF-b-RI) were highly decreased in
Set9-deficient lung fibroblasts and HeLa cells (Figure S4).Loss of Set9 Protects against Bleomycin- or Ad-TGF-
b-Mediated Pulmonary Fibrosis in Mice
The in vivo relevance of these findings was assessed in the path-
ological condition of lung fibrosis, as uncontrolled expression of
ECMgenes is a hallmark feature of this disease (Wynn, 2011).We
tested bleomycin-induced pulmonary fibrosis, the best-charac-
terized and most widely used model for the disease (Moore
and Hogaboam, 2008; Della Latta et al., 2015). Bleomycin treat-
ment of WT mice resulted in a characteristic lung histology
phenotype of interstitial thickening, alveolar collapse, and the
presence of cystic air spaces (Figure 5A). These pathological
features were highly reduced in Set9-deficient mice (Figure 5A).
The protective effect of Set9 depletion was confirmed by Sirius
red and Masson’s trichrome staining, which revealed decreased
cross-linked collagen fiber deposition in the lungs of Set9-KO
mice (Figures 5A, 5C, and S5A).
The pathogenesis of pulmonary fibrosis in the bleomycin
model involves severe tissue damage, followed by the accumu-
lation of inflammatory cells and pro-fibrogenic cytokine secre-
tion, which in turn induce collagen production by resident fibro-
blasts or by myofibroblasts derived from transdifferentiation of
epithelial cells (Wynn, 2011; Moore and Hogaboam, 2008; Liu
et al., 2010). Impairment of one of these early events could
explain the reduced fibrotic response in Set9-KO mice. Our im-
munostaining experiments, with the pan-leukocyte marker
CD45 and the myofibroblast marker aSma, demonstrate that
Set9 inactivation does not affect bleomycin-mediated accumu-
lation of these cell types (Figure S5B). These findings suggest
that Set9 is specifically required for later stages of the fibrotic
process, such as the production or deposition of ECM compo-
nents. The possibility that bleomycin-mediated damage may in-
fluence Set9 expression was excluded by western blot analysis,
which showed similar amounts of Set9 protein in untreated and
bleomycin-treated lungs (Figure S6A).
Although TGF-b is recognized as themainmediator of bleomy-
cin-induced pulmonary fibrosis, intrinsic changes in the activa-
tion of epithelial cells or fibroblasts, such as activation of Wnt-
b-catenin signaling or defects in PTEN-dependent suppression
of PI3K-Akt-S6K1 pathway, may promote growth factor-inde-
pendent fibrotic responses (Ko¨nigshoff et al., 2009; Xia et al.,
2008). Therefore, we analyzed the effect of Set9 deficiency on
the pulmonary fibrosis phenotype in another experimental
model, involving intratracheal delivery of TGF-b-producing
adenovirus (Ad-TGF-b) (Koltsida et al., 2011). Similar to bleomy-
cin treatment, Set9-KO mice developed highly reduced fibrotic
lesions following Ad-TGF-b instillation compared toWT counter-
parts (Figures 5B and 5C).
In agreement with the morphological data, significant differ-
ences betweenWT and Set9-KOmice were detected in lungme-
chanic parameters following bleomycin or Ad-TGF-b challenge:
the static compliance (Cst), which reflects the elastic recoil of the
lung at a given pressure, and the dynamic compliance (Cdyn),
which captures the ease with which the lungs can be extended,
were decreased to a much lesser extent in Set9-KOmice than in
WT littermates (Figures 5D and 5E).
The mechanistic basis of the above histological and physio-
logical phenotypes was revealed by the analysis of ECM gene
expression profiles. The activation of a large panel of ECMCell Reports 15, 2733–2744, June 21, 2016 2737
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genes, including collagens (Col1A1, Col3A1, and Col4A2), con-
nective tissue growth factor (Ctgf), fibrillin (Fbn), fibronectin
(Fn), integrin-5A (Itg5A), keratin-17 (Krt17), and Serpine1, was
greatly diminished in the lungs of bleomycin-treated Set9-KO
mice (Figure 6A). Similar to the observations in the bleomycin
model, Ad-TGF-b-induced activation of ECM genes was highly
compromised in Set9-KO mice (Figure 6B).
In the lungs of both bleomycin- and Ad-TGF-b-treated mice,
the mRNA levels of several well-characterized regulators of the
EMT process (HmgA2, Has, Twist, and Snai1) were significantly
increased, while those of E-cadherin (Cdh1) decreased (Figures
S6B and S6C). These effects were largely prevented in the lungs
of Set9-KO mice (Figures S6B and S6C). The above data were
obtained with RNAs from total lung tissue containing different
cell populations. The particular cell type(s) where EMT takes
place remains to be determined. Notwithstanding this limitation,
the impaired activation of another group of TGF-b target genes in
Set9-KO mice provides additional support for the in vivo role of
Set9 function in TGF-b signaling.
DISCUSSION
The results of this study demonstrate that the methyltransferase
Set9 is required for the development of pulmonary fibrosis, and
they identify Set9 as a potential candidate therapeutic target
for treatment of the disease.
Complete loss of Set9 in mice did not lead to macroscopically
visible lung phenotypes under normal conditions. This was
surprising, since Set9 is known to methylate several regulatory
proteins, which control diverse biological processes such as
cell growth, apoptosis, metabolism, and hormonal or cytokine
signaling (Chuikov et al., 2004; Subramanian et al., 2008; Prad-
han et al., 2009; Yang et al., 2010; Kontaki and Talianidis,
2010a, 2010b; Munro et al., 2010; Carr et al., 2011; Sarris
et al., 2014). Our failure to detect major phenotypic changes in
Set9-KO mice indicates that Set9 is redundant to normal lung
development and function, either due to the activation of fac-
tor(s) and/or alternative pathways, which compensate its func-
tion, or because Set9-mediated methylation of the target pro-
teins may have only minor, fine-tuning effects. In pathological
situations, however, when specific biological processes are hy-
peractivated or repressed, themodulatory effects of posttransla-
tional modifications may be manifested in a more dominant
manner. This is likely the case with Set9 function, since under
cellular damage conditions triggering lung fibrosis, Set9-KOFigure 3. Methylation Prevents Acetylation and Promotes Smad7 Ubiq
(A) Whole-cell extracts from HeLa cells treated with 5 ng/ml TGF-b and 5 mMMG1
antibodies. Immunoprecipitated proteins were analyzed in western blots with a-
(B) Set9 depletion reduces Smad7 polyubiquitination. Extracts fromWT and sh-Se
TGF-b and 5 mMMG132 for 5 hr were subjected to IP with aSmad7 (rabbit polyclo
aUbiquitin or aSmad7 antibodies.
(C) Methylation of Smad7 promotes polyubiquitination. HeLa cells were transfecte
Whole-cell extracts were immunoprecipitated with aHA antibody and analyzed i
(D–F) Methylated Smad7 interacts with Arkadia. Extracts fromWT and sh-Set9He
b and 5 mMMG132 for 5 hr were used for IPs with aSmad7 or aMe-Smad7 antibod
or a-Smurf2 (F) antibodies. Before IPs, the extracts were diluted to obtain input ma
the immunoprecipitates were verified in separate gels using aSmad7 antibody (b
See also Figure S3.mice exhibited a robust and clinically relevant phenotype. The
strong protective effect of Set9 deficiency on the development
of pulmonary fibrosis in two different mouse models warrants
further studies in human subjects, as Set9 inhibitors could be
considered in treating the disease at the early, developing
stages. The essentially normal phenotype of Set9-KO mice in
physiological conditions provides the expectation that pharma-
cological inhibition of Set9 may have negligible side effects.
Excessive production and accumulation of ECM proteins is
the hallmark event of fibrotic diseases, including pulmonary
fibrosis (Wynn, 2011). Our findings suggest that Set9 function
is required for TGF-b-dependent activation of ECM genes. We
identified Smad7, the inhibitory molecule of the TGF-b-signaling
pathway, as a bona fide enzymatic target of Set9, and we pro-
vide evidence for the role of methylation-mediated destabiliza-
tion of Smad7 in the regulation of ECM gene expression.
Previous studies have established that Smad7 is subject to
reversible acetylation, which prevents Smurf1-dependent ubiq-
uitination and degradation (Gro¨nroos et al., 2002; Ogunjimi
et al., 2005; Simonsson et al., 2005). Non-acetylated Smad7
molecules can exit the nucleus, interact with Smurf1/2 E3 li-
gases, and escort them to the plasma membrane, where they
ubiquitinate TGF-b receptor (TbRI and TbRII), parallel to the ubiq-
uitination of Smad7 proteins. Subsequent proteasomal degrada-
tion of both leads to feedback inhibition of TGF-b signal trans-
duction. Our results reveal an additional level of complexity in
the interplay of posttranslational modifications that regulate
Smad7 stability (see scheme in Figure 6C). According to this
model, the size of the non-acetylated pool of Smad7 is controlled
by Set9-mediated methylation. Methylated Smad7 selectively
interacts with the E3 ligase Arkadia, which catalyzes ubiquitina-
tion and facilitates its proteasomal degradation. When Set9 ac-
tivity is inhibited, Arkadia-mediated clearance of Smad7 is
blocked, leading to the expansion of the pool of non-modified
Smad7 molecules available for interaction with Smurf1/2 E3 li-
gases and Smurf-mediated destruction of the TGF-b receptor
complex. In this way, Set9 deficiency or pharmacological inhibi-
tion of its activity prevents activation of TGF-b-induced genes,
including those encoding for ECM components.
Previous studies have established that Arkadia interacts only
with the C-terminal domain of Smad7 and that this interaction
is stimulated by Axin (Koinuma et al., 2003; Liu et al., 2006). On
the other hand, Axin can interact with both the N-terminal and
C-terminal parts of Smad7 (Liu et al., 2006). Set9-mediated
methylation of the K70 lysine residue at the N-terminal regionuitination
32 for 5 hr were used for IPs with aSmad7 (rabbit polyclonal) and aMe-Smad7
panacetyl-lysine (upper panel) or aSmad7 (lower panel) antibodies.
t9HeLa cells orWT andSet9-KO lung fibroblasts that were treatedwith 5 ng/ml
nal) antibody. Immunoprecipitated proteins were analyzed in western blots with
d with the indicated expression vectors and treated with 5 mMMG132 for 5 hr.
n western blots with aUbiquitin or aSmad7 antibodies.
La cells orWT andSet9-KO lung fibroblasts that were treatedwith 5 ng/ml TGF-
ies, and they were analyzed in western blots using a-Arkadia (D), a-Smurf1 (E),
terials with equal amounts of Smad7. Equal loadings of total Smad7 proteins in
ottom panels).
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Figure 4. Arkadia Preferentially Interacts
with Methylated Smad7 and Promotes Its
Ubiquitination
(A) In vitro interactions of Smad7 with Arkadia,
Smurf1, and Smurf2 proteins. Recombinant His6-
tagged Smad7 proteins immobilized on TalonTM
Ni-affinity column were preincubated with GST-
Set9 in the absence (His-Smad7) or presence (His-
Smad7-Me) of 1 mM S-adenosyl-methionine. The
beads were then incubated with extracts from
HeLa cells that were transfected with CMV-Arka-
dia (left panel), CMV-Smurf1 (middle panel), and
CMV-Smurf2 (right panel). The presence of Arka-
dia, Smurf1, and Smurf2 proteins in the Smad7-
containing beads was evaluated by western blot
analysis.
(B) Non-methylated and methylated His-Smad7
proteins immobilized in TalonTM beads as in (A)
were incubated with in-vitro-translated 35S-
methionine-labeled full-length Arkadia (Ark) or
Axin2 proteins (corresponding to 10 ng of trans-
lated protein), as indicated. In the right panel, the
beads were incubated with a mix of unlabeled
Axin2 translation product (30 ng Axin2 protein) and
35S-Arkadia (10 ng protein) under the same
conditions. After washings, bound 35S-Arkadia or
35S-Axin2 proteins were detected by SDS-PAGE
followed by autoradiography.
(C) HeLa cells were transfected with Arkadia-
specific smart pool siRNAs or control siRNA. Then
3 days after transfection, endogenous levels of
Arkadia (first panel), methylated Smad7 (third
panel), total Smad7 (fourth panel), and Gapdh (fifth
panel) were evaluated by western blot analysis. In
the experiment shown in the second panel, cells
that were transfected with Arkadia-specific siRNA
were co-transfected 36 hr before harvest with
CMV-Arkadia plasmid, containing the mouse ORF
of the gene.
(D) HeLa cells were transfected with the indi-
cated expression vectors and treated with 5 mM
MG132 for 5 hr. Transfections of siRNAs and
the mammalian expression vectors (CMV-HA-
Smad7wt, CMV-Myc-Set9wt, and CMV-Arkadia)
were performed 72 and 36 hr before harvest,
respectively. Whole-cell extracts were immuno-
precipitated with aHA antibody and analyzed in
western blots with aUbiquitin or aSmad7 anti-
bodies.
(E) Control siRNA or Arkadia-specific siRNA-transfected HeLa cells were re-transfected with pCMV-HA-Smad7 (HA-Smad7wt) and pCMV-myc-Set9 (Set9wt) as
in (C). Before harvesting, the cells were treated with 50 mg/ml CHX for the indicated times. Whole-cell extracts were analyzed in western blots using anti-Me-
Smad7 or anti-HA (a-HA) antibodies as indicated. One representative of two experiments is shown. The graph shows band intensities, measured by ImageJ
software, relative to untreated controls.
See also Figure S4.of Smad7 did not affect direct interaction with Axin2. However,
selective interaction of Arkadia with methylated Smad7 was
absolutely dependent on Axin2, suggesting that the latter may in-
fluence the overall structure of the non-methylated and methyl-
ated protein in distinct manners. Axin2 binding to methylated
Smad7 may generate a configuration optimal for interaction
with Arkadia. Future studies will be required to obtain structural
insights into this interaction, which may facilitate the develop-
ment of novel pharmaceutical intervention strategies aimed at2740 Cell Reports 15, 2733–2744, June 21, 2016the modulation of Smad7 stability, in addition to the abovemen-
tioned Set9 enzyme inhibitors.EXPERIMENTAL PROCEDURES
Animals and Treatments
The generation of Set9-KO mice by gene targeting is described in Figure S1.
Mice that were used in this study had a mixed C57Bl6/CBA genetic back-
ground. Mice were maintained in grouped cages in a temperature-controlled,
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Figure 5. Set9 Deficiency Confers Resis-
tance to Mice against Bleomycin- or Ad-
TGF-b-Induced Pulmonary Fibrosis
(A) Representative H&E and Sirius red staining of
lung sections of WT and Set9-KO mice after
bleomycin treatment (n = 5). Control mice were
treated with PBS (n = 5).
(B) Representative H&E and Sirius red staining of
lung sections of WT and Set9-KO mice after Ad-
TGF-b (n = 7) treatment. Control mice were treated
with empty Adenoviral vector (Ad-0) (n = 6).
(C) Quantitation of Sirius red-positive areas in 20
different high-power fields in lung sections of
each untreated, bleomycin-, or Ad-TGF-b-treated
WT and Set9-KO mice. Data are presented as
mean ± SEM (*p value < 0.0001, two-tailed Stu-
dent’s t test).
(D) Effect of Set9 deficiency on bleomycin-induced
changes of lung mechanics. Static (Cst) and dy-
namic (Cdyn) compliance percentage differences
(bleomycin- versus PBS-treated mice) in response
to bleomycin-induced injury are shown. Bars
represent mean values ± SEM from n = 5 PBS-
treated WT mice, n = 5 bleomycin-treated WT
mice, n = 3 PBS-treated Set9-KO mice, and n = 4
bleomycin-treated Set9-KO (*p < 0.05, two-tailed
Student’s t test).
(E) Effect of Set9 deficiency on Ad-TGF-b-induced
changes of lung mechanics. Static (Cst) and dy-
namic (Cdyn) compliance percentage differences
(Ad-TGF-b versus Ad-0-treated mice) in response
to Ad-TGF-b-induced injury are shown. Bars
represent mean values ± SEM from n = 5 Ad0-
treated WT mice, n = 5 Ad-TGF-b-treated WT
mice, n = 4 Ad-0-treated Set9-KO mice, and n = 7
Ad-TGF-b-treated Set9-KO mice (*p < 0.05, two-
tailed Student’s t test).
See also Figure S5.pathogen-free facility on a 12-hr light/dark cycle, and they were fed a standard
chow diet (Altromin 1324; 19% protein and 5% fat) and water ad libitum.
Anesthetized, 12-week-old male Set9-KO and WT mice (weight 28–34 g)
were treated intratracheally with 0.033 U/mouse bleomycin (Nippon Kayaku)
diluted in endotoxin-free PBS, or PBS alone (vehicle), in 30 ml total volume. An-
imals were analyzed on days 5 and 15 post-bleomycin treatment.
For intratracheal instillation of recombinant adenovirus, a total of 23 108 in-
fectious particles of adenoviruses expressing porcine, biologically active TGF-
b1 (Ad-TGF-b1223/225), or a control virus (Ad-0) were used in 40 ml total volume
as described (Koltsida et al., 2011). Animals were analyzed on day 14 post-
adenovirus instillation.
All animal experiments were approved by the Prefecture of Attica and the
Institutional ReviewBoard of Biomedical Sciences ResearchCenter Alexander
Fleming, and they were performed in accordance with the respective national
and European Union regulations. All the experiments were performed in
randomly chosen age-matched male mice. No blinding was used in this study.Cell RHistological Analysis
Histological assays were performed in paraffin-
embedded or frozen tissue sections as described
previously (Apostolou et al., 2012; Nikolaou et al.,
2012, 2015). Briefly, lungs were dissected, fixed
in 4% paraformaldehyde, and embedded in
paraffin. Lung sections (5–6 mm thick) were boiled
in 10mMNa-citrate for 20min, and, after washings
with PBS, the sections were blocked with normal
goat serum and used for staining with the aSMAand aCD45 antibodies using AlexaFluor 568 and 488 (Molecular Probes) sec-
ondary antibodies. After counterstaining with DAPI, fluorescence images were
observed using a Zeiss Axioscope 2 Plus microscope. Paraffin-embedded tis-
sue sections were used for staining with H&E or with 0.1% Sirius red dissolved
in saturated picric acid, as described previously (Nikolaou et al., 2012, 2015).
Sirius red-positive areas were quantitated using NIH ImageJ software.
Cell Culture and Transfections
For the isolation of primary lung fibroblasts, lung tissue from WT and Set9-KO
mice was cut into small pieces in cold PBS, and it was incubated in a buffer
containing 0.1% collagenase (Roche), 2.4 U/ml Dispase, 2 mM CaCl2,
150 mM NaCl, and 10 mM HEPES (pH 7.9) for 1.5 hr at 37C with constant
shaking. Liberated cells were drained through a 70-mm mesh filter and
collected by centrifugation at 1,500 rpm for 5 min. The cells were washed
twice with DMEM-F12 and resuspended in DMEM-F12/10% fetal calf serum
(FCS), 100 U/ml penicillin/streptomycin-containing medium. Then 4 hr aftereports 15, 2733–2744, June 21, 2016 2741
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Figure 6. Set9 Is Required for Bleomycin-
and Ad-TGF-b-Dependent Activation of
ECMGenes
(A) qPCR analysis of the mRNA levels of the indi-
cated panel of ECM genes in reverse-transcribed
total lung RNAs from WT and Set9-KO mice after
treatment with PBS (C) or bleomycin (Ble). Bars
represent mean values of mRNA levels normalized
to Gapdh mRNA ± SEM. Data are from triplicate
measurements of total RNAs from five individual
mice (*p < 0.05, two-tailed Student’s t test).
(B) qPCR analysis of mRNA levels of the indicated
ECM genes in reverse-transcribed total lung
RNAs from WT and Set9-KO mice after treatment
with empty adenovirus vector (C) or Ad-TGF-b.
Bars represent mean values of mRNA levels
normalized to Gapdh mRNA ± SEM. Data are
from triplicate measurements of total RNAs
from five individual mice (*p < 0.05, two-tailed
Student’s t test).
(C) Schematic presentation shows methylation-
ubiquitination-acetylation interplay in balancing
intracellular Smad7 levels.
See also Figure S6.transferring to plates, floating cells were removed by changing the medium.
The culture medium was changed again after 24 and 48 hr.
HeLa cells (ATCC) were maintained in DMEM supplemented with 10%
FCS and 100 U/ml penicillin/streptomycin. Sh-Set9-expressing HeLa cell
line was generated by transfecting pRS-Set9 vector (OriGene) harboring the
following short hairpin sequence: 50 GAT CGA TGA CTG GAG AGA AGA
TAG CCT ATG TGT TCA AGA GAC ACA TAG GCT ATC TTC TCT CCA GTC
ATC TTT TT. Cells stably expressing sh-Set-9 were obtained by selection
with 0.5 mg/ml puromycin. Tranfections of HeLa cells were performed using
Jet-PEI reagent (Polyplus).
Vectors expressing HA-tagged WT and mutant forms of Smad7 were con-
structed by cloning the open reading frame (ORF) of human Smad7 into
pCMV-HA vector (Kontaki and Talianidis, 2010a). pCMV-Myc-Set9wt and
pCMV-myc-Set9 H297A have been described (Kontaki and Talianidis,
2010a). Mammalian expression vectors for Arkadia (pCMV6-RNF111), Smurf1
(pCMV6-Smurf1), and Smurf2 (pCMV6-Smurf2) were obtained from OriGene.
SiRNA-mediated knockdown of Arkadia or Smad7 in HeLa cells was achieved
by transfection of predesigned ON-TARGET plus SMART pool human RNF1112742 Cell Reports 15, 2733–2744, June 21, 2016siRNAs or Smad7 siRNAs (Dharmacon) using
DharmaFECT transfection reagent. The cells
were used for analyses 72 hr following transfec-
tion. In reconstitution experiments, 36 hr before
harvesting, the cells were transiently transfected
with CMV-RNF111 mouse ORF clone using Jet-
PEI reagent. Mutagenesis was performed with
GeneEditor kit (Promega).
IPs and Western Blot Analysis
Cells were lysed by resuspension in 10 vol modi-
fied radio-IP assay (RIPA) buffer containing
50 mM Tris (pH 7.5), 1% NP40, 0.25% Na-Deoxy-
cholate, 150mMNaCl, 1mMEDTA, 10%Glycerol,
1 mM NaF, and protease inhibitors cocktail
(Roche). After 20-min incubation by shaking at
4C, extracted proteins were recovered by centri-
fugation at 14,000 rpm for 10 min. In IP assays,
cellular lysates were incubated with 2–5 mg anti-
bodies and 30-ml bed volume of Protein-G-Se-pharose beads (Millipore) for 5 hr at 4C, followed by four successive washes
with modified RIPA buffer. For IP-western blot assays analyzing ubiquitinated
proteins, the RIPA extraction buffer contained 0.5% SDS and the lysates were
diluted five times with RIPA buffer without SDS before IP. Extracts and immu-
noprecipitated proteins were resolved by 10%, 12%, or 6%SDS-PAGE, trans-
ferred to nitrocellulose membrane, and analyzed by western blot as described
(Hatzis et al., 2006).
The antibodies used in this study are described in the Supplemental Exper-
imental Procedures.
In Vitro Methylation Assays
The ORFs of human Smad2, Smad3, Smad4, and Smad7 cDNAs were subcl-
oned into PRSET-A vector, in frame of the 6xHis-tag sequence, and used for
transformation of BL21(DE3)-competent cells. Recombinant proteins from
the extracts of IPTG-induced bacteria were affinity purified using TALON
beads (Clontech Laboratories). GST-Set9 protein was purified by glutathione
Sepharose affinity chromatography, as described previously (Kontaki and Ta-
lianidis, 2010a).
In vitro methylation assays were performed by incubation of GST-Set9 with
purified recombinant Smad proteins with 1 mCi 3H-SAM (S-adenosyl-methio-
nine) in a buffer containing 50 mM Tris-HCl (pH 9.1), 0.5 mM DTT, and 4 mM
EDTA for 1 hr at 30C. The reactions were stopped by adding SDS-PAGE
loading buffer and analyzed by SDS-PAGE and fluorography.
For the analysis of protein-protein interactions with unmethylated or preme-
thylated Smad7, TalonTM Ni-affinity beads containing His6-Smad7 were incu-
bated with GST-Set9 for 2 hr at 30C, in the presence or absence of 1 mM cold
SAM in a buffer containing 50 mM Tris-HCl (pH 9.1) and 10 mM NaCl. The
beads were washed with modified RIPA buffer lacking EDTA, and they were
incubated with extracts of HeLa cells that were transfected with Arkadia,
Smurf1, or Smurf2 expression vectors for 5 hr at 4C with constant rotation.
For the analyses of direct protein interactions in vitro, 35S-methionine labeled
Arkadia and Axin2 were synthesized by the TnT Quick Coupled Transcription/
Translation System (Promega), according to the manufacturer’s instructions.
The translation products were diluted in modified RIPA buffer lacking EDTA
and incubated with the beads as above. After extensive washing with modified
RIPA buffer lacking EDTA, interacting proteins were detected by western blot
analysis (in assays with cellular extracts) or by autoradiography (in assays with
in-vitro-synthesized proteins).
RNA Analysis
Total RNA was prepared by the Trizol extraction protocol (Tatarakis et al.,
2008). After digestion with DNase I, 1 mg total RNA was used for first-strand
cDNA synthesis using Moloney murine leukemia virus (MMLV) reverse tran-
scriptase. The qPCR analyses were carried out in STEP1 Real-time PCR
detection system by using SYBRGreen reagent as described before (Tatarakis
et al., 2008; Nikolaou et al., 2015). The nucleotide sequences of primer sets
used are described in the Supplemental Experimental Procedures.
Statistical Analysis
Data are reported as mean values from the number of replicates indicated in
the legends, with error bars denoting ±SEM. Statistical significance was eval-
uated by two-tailed Student’s t test.
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